January 8, 2021

Graphite Bio to Present at the 39th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Graphite Bio, a next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced that Josh Lehrer, M.Phil, M.D., chief executive officer, will present an overview of Graphite Bio's corporate strategy, business priorities and upcoming clinical milestones at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021, at 2:00 p.m. Eastern Time / 11:00 a.m. Pacific Time.

A recording of the webcast will be made available after the presentation at www.graphitebio.com in the Top News section for approximately 30 days.

About Graphite Bio

Graphite Bio is a next-generation gene editing company focused on the development of potentially curative therapies for patients suffering from serious diseases. The company's targeted gene integration platform harnesses the natural cellular process of homology directed repair (HDR) to efficiently repair genetic defects at their source, deliver genetic cargo with precision and engineer new cellular effector functions. Graphite Bio is leveraging its differentiated platform, initially focused on ex vivo engineering of hematopoietic stem cells, to advance a portfolio of transformative treatments with potential for saving and dramatically improving patients' lives. The company was co-founded by academic pioneers in the fields of gene editing and gene therapy, including Maria Grazia Roncarolo, MD, and Matthew Porteus, MD, PhD, and is backed by Versant Ventures and Samsara BioCapital. For more information, please visit www.graphitebio.com.

View source version on businesswire.com:
https://www.businesswire.com/news/home/20210108005565/en/

Christy Curran
615.414.8668
media@graphitebio.com

Source: Graphite Bio